Access Dermatology

Latest Clinical Trials

• Pimecrolimus in atopic dermatitis

  Summary

  Pimecrolimus cream 1% for the treatment of facial atopic dermatitis: Exploratory analysis of a double-blind, randomized, vehicle-controlled study in pediatric patients

• Adalimumab in psoriasis: The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis TriAL)

  Summary

  Psoriasis patients treated continuously with adalimumab: Efficacy and safety results from months 12 to 18

• Etanercept in psoriasis

  Summary

  Etanercept 50 mg once weekly is effective and well tolerated in patients with moderate to severe plaque psoriasis

• Methyl aminolevulinate in keratosis

  Summary

  Results from two randomized, multicenter, vehicle-controlled studies evaluating the efficacy and safety of methyl aminolevulinate-photodynamic therapy for the treatment of actinic keratoses

• Adalimumab in rheumatoid arthritis

  Summary

  Adalimumab safety profile in global clinical trials and reduction in standardized mortality ratios (SMR) across multiple indications

• Clobetasol vs. calcipotriene and betamethasone in psoriasis

  Summary

  Results from a randomized study comparing clobetasol propionate 0.05% spray to calcipotriene 0.005%, betamethasone dipropionate 0.064% ointment for the treatment of plaque psoriasis

• Infliximab in psoriasis

  Summary

  Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: Results from controlled clinical trials

• Infliximab in psoriasis: The EXPRESS II (Evaluation of Infliximab for Psoriasis in a Remicade Efficacy and Safety Study)

  Summary

  In situ analysis of psoriatic plaques upon infliximab treatment

• Calcipotriene plus betamethasone in psoriasis

  Summary

  A 1-year, randomized, double-blind safety study of long-term treatment of a new gel formulation containing calcipotriene plus betamethasone dipropionate in scalp psoriasis

• Desonide in atopic dermatitis

  Summary

  The importance of vehicle properties to atopic dermatitis patients: A preference study with a novel desonide hydrogel treatment